Loading
Drugs that block EGFR, such as cetuximab, panitumumab, amivantamab and EGFR tablets for lung cancer, very often cause an acne-like rash. Starting skin care on day one makes a bad rash much less likely: doxycycline or minocycline for the first weeks, moisturiser, sunscreen, and sometimes a mild steroid cream. Tell your team early if it spreads or hurts: a pause or lower dose may help.
The MASCC Skin Toxicity Study Group (2011) recommends pre-emptive management for EGFR inhibitor rash because it is frequent and appears in the first 2 to 4 weeks: hydrocortisone 1 per cent with moisturiser and sunscreen twice daily, plus doxycycline 100 mg twice daily (or minocycline 100 mg daily) for the first 6 weeks, based on the randomised STEPP trial. In STEPP (panitumumab, 95 people), protocol-specified grade 2 or worse skin toxicity in 6 weeks fell from 62 to 29 per cent; J-STEPP repeated the result in Japanese patients (62.5 to 21.3 per cent). A 2022 meta-analysis found oral antibiotics reduced grade 2 or worse rash by 40 per cent; topical antibiotics, vitamin K1 cream and sunscreen alone were not significant. For amivantamab, the 2026 US label now recommends the COCOON regimen at initiation: doxycycline or minocycline 100 mg twice daily for 12 weeks, then clindamycin 1 per cent lotion to the scalp for 9 months, a non-comedogenic moisturiser, daily 4 per cent chlorhexidine for hands and feet, and sun protection; in the COCOON trial (amivantamab with lazertinib, 201 people) it reduced grade 2 or worse dermatologic events by week 12 from 75 to 42 per cent. Doubts remain: in a post hoc analysis of the Valentino trial of first-line panitumumab, doxycycline prophylaxis did not significantly lower rash. Dose rules come from labels: panitumumab is withheld for 1 to 2 doses at grade 3 and restarted at 100, 80 then 60 per cent by occurrence. The ESMO 2021 guideline could not be read.
Why: The rash is very common and comes in the first weeks; treating early prevents most of the severe cases.
“Based on the high frequency of rash in EGFRI-treated patients and the consistent presentation within the first 2–4 weeks of therapy, preventive/prophylactic management is recommended unless there are contraindications based on patient and/or health care provider factors [ 6 – 12 ].”
MASCC Skin Toxicity Study Group, Supportive Care in Cancer 2011 · Level II, grade A (systemic tetracycline)
Why: The antibiotic is used for its anti-inflammatory effect on the skin, not for infection; with gentle skin care it halved moderate rash in the trial behind this advice.
“Hydrocortisone 1% combined with moisturizer, sunscreen, and doxycycline 100 mg bid for the first 6 weeks is recommended based on randomized data.”
MASCC Skin Toxicity Study Group, Supportive Care in Cancer 2011 · Level II, grade A (tetracycline); Level II, grade C (topical hydrocortisone with moisturiser and sunscreen)
Why: Amivantamab causes rash, scalp and nail problems over many months; a longer regimen covering the scalp reduced moderate skin problems in a randomised trial.
“Administer an oral antibiotic (doxycycline or minocycline, 100 mg orally twice daily) starting on Day 1 for the first 12 weeks of treatment.”
Janssen Biotech, via DailyMed (US National Library of Medicine) 2026 · US prescribing information
Why: Moisturiser protects dry skin; the antiseptic wash aims to prevent infection around the nails (paronychia).
“Wash hands and feet with 4% chlorhexidine solution once daily.”
Janssen Biotech, via DailyMed (US National Library of Medicine) 2026 · US prescribing information
Why: Sunlight makes the rash worse, and some of the tetracyclines make skin more sensitive to sun.
“Advise patients to limit sun exposure (use sunscreen, wear hats) while receiving Vectibix and for 2 months after the last dose of Vectibix therapy”
Amgen, via DailyMed (US National Library of Medicine) 2026 · US prescribing information
Why: The rash is inflammatory rather than true acne, so anti-inflammatory creams help; acne creams that dry the skin can make it worse.
“Reactive use of medium- to high-potency topical corticosteroids is recommended based on studies showing in vitro release of inflammatory chemokines after EGFRI therapy.”
MASCC Skin Toxicity Study Group, Supportive Care in Cancer 2011 · Level IV, grade C
Why: A pause lets the skin settle while keeping the treatment going; repeated severe rashes need a lower dose.
“Upon first occurrence of a Grade 3 (NCI-CTC/CTCAE) dermatologic reaction, withhold 1 to 2 doses of Vectibix. If the reaction improves to < Grade 3, reinitiate Vectibix at the original dose.”
Amgen, via DailyMed (US National Library of Medicine) 2026 · US prescribing information
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
Pre-emptive treatment from day 1 with an oral tetracycline, moisturiser, sunscreen and a mild topical steroid is the best-supported approach for EGFR antibodies, on the MASCC 2011 guideline (systemic tetracycline Level II, grade A) and two randomised trials (STEPP, J-STEPP), and oral antibiotics are the only preventive measure significant in the 2022 meta-analysis. For amivantamab the US label now builds the COCOON regimen into dosing, on the strength of a randomised trial. The evidence is not uniform: a post hoc analysis of first-line panitumumab in the Valentino trial found no significant reduction in rash with doxycycline. The ESMO 2021 dermatological toxicity guideline, the most recent international guideline, could not be read, and MASCC has not updated its 2011 guideline in any source found.
MASCC Skin Toxicity Study Group, Supportive Care in Cancer 2011 · Journal of Clinical Oncology 2010 · Future Oncology 2015 · Asia-Pacific Journal of Clinical Oncology 2022 · Janssen Biotech, via DailyMed (US National Library of Medicine) 2026 · Journal of Thoracic Oncology 2025 · Supportive Care in Cancer 2021 · ESMO, Annals of Oncology 2021
Where it differs: Twelve weeks of oral doxycycline or minocycline (rather than 6), then 9 months of clindamycin 1 per cent on the scalp, chlorhexidine 4 per cent on fingernails and toenails, and ceramide-based moisturiser at least daily.
Evidence: Randomised phase 2 trial of 201 people: grade 2 or worse dermatologic adverse events of interest by week 12 in 42 per cent against 75 per cent with standard care (odds ratio 0.24); patient-reported quality of life favoured the regimen. Now in the US amivantamab label.
Journal of Thoracic Oncology 2025 · Janssen Biotech, via DailyMed (US National Library of Medicine) 2026
Where it differs: Treating rash when it appears rather than with routine prophylaxis.
Evidence: Post hoc, non-randomised comparison within the Valentino trial (226 people): any-grade rash 81 per cent with doxycycline prophylaxis against 90 per cent without (P = 0.085), grade 3 or 4 rash 27 against 25 per cent; no difference in dose delays, reductions or survival.
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Pre-emptive skin treatment halved grade 2 or worse skin toxicity with panitumumab (STEPP) “The incidence of protocol-specified >or= grade 2 skin toxicities during the 6-week skin treatment period was 29% and 62% for the pre-emptive and reactive groups, respectively.” | randomised phase 2 open-label trial, n = 95 | Journal of Clinical Oncology 2010 |
| The result was repeated in Japanese patients (J-STEPP) “The primary end point was achieved (21.3 and 62.5% [risk ratio: 0.34; p < 0.001], for pre-emptive and reactive treatment, respectively).” | randomised open-label trial, n = 95, P < 0.001 | Future Oncology 2015 |
| Oral antibiotics reduced grade 2 or worse acneiform rash by 40 per cent “Oral antibiotics had the greatest efficacy in preventing grade 2 or higher acneiform eruptions with a relative risk reduction of 40% (RR = .6, 95% CI .46-.79, p < .01).” | systematic review and meta-analysis | Asia-Pacific Journal of Clinical Oncology 2022 |
| The COCOON regimen reduced grade 2 or worse dermatologic events with amivantamab and lazertinib “At a median follow-up of 7.1 months, COCOON DM demonstrated significant reduction in the primary end point versus SoC DM (42% versus 75%; OR, 0.24; 95% confidence interval, 0.13-0.45; p < 0.0001).” | randomised phase 2 trial, n = 201, p < 0.0001 | Journal of Thoracic Oncology 2025 |
Shares Rash and skin toxicity (acneiform rash, paronychia), Afatinib, Gefitinib, Erlotinib.
Shares Afatinib, Lazertinib, Gefitinib, Erlotinib.
Shares the tags protocol, skin-toxicity, supportive-care.
Shares Panitumumab, Cetuximab and the tags protocol, supportive-care.
Shares Living with FOLFOX, CAPOX, FOLFIRI and the EGFR antibodies and the tags protocol, supportive-care.
Shares Lazertinib, Gefitinib, Erlotinib, Amivantamab.
Shares the tags protocol, supportive-care.
Shares the tags protocol, supportive-care.